Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Blood. 2013 Jun 6;121(23):4718-28. doi: 10.1182/blood-2012-12-470153. Epub 2013 Apr 30.
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults. Aberrant activation of Hedgehog (Hh) and nuclear factor (NF)-κB pathways is ubiquitously observed and known to mediate tumor growth, survival, and chemoresistance in DLBCL. Here, we find that activation of Hh signaling is positively correlated with NF-κB pathway in DLBCL tumors, and that smoothened (SMO), the signal transducer subunit of Hh pathway, contributes to NF-κB activation through recruiting G protein subunits Gαi and Gα12 to activate PKCβ/CARMA1/TRAF6/NEMO signaling axis followed by assembling of the CARMA1/BCL10/MALT1/TRAF6 complex to SMO. Moreover, functional inhibition of SMO enhances the cytotoxic effects of NF-κB inhibitor. Altogether, our study reveals a noncanonical Hh signaling pathway in which SMO activates trimeric G proteins and CARMA1-associated signaling complex, leading to NF-κB activation. This signaling cascade contributes to the survival of DLBCL and may serve as a potential target for combination therapies in DLBCL.
弥漫性大 B 细胞淋巴瘤(DLBCL)是成人中最常见的淋巴恶性肿瘤。Hedgehog(Hh)和核因子(NF)-κB 通路的异常激活在 DLBCL 中普遍存在,并已知介导肿瘤生长、存活和化疗耐药性。在这里,我们发现 Hh 信号通路的激活与 NF-κB 通路在 DLBCL 肿瘤中呈正相关,并且 Hh 通路的信号转导亚基 smoothened(SMO)通过招募 G 蛋白亚基 Gαi 和 Gα12 来激活 PKCβ/CARMA1/TRAF6/NEMO 信号轴,从而有助于 NF-κB 激活,随后组装 CARMA1/BCL10/MALT1/TRAF6 复合物到 SMO。此外,SMO 的功能抑制增强了 NF-κB 抑制剂的细胞毒性作用。总之,我们的研究揭示了一条非典型的 Hh 信号通路,其中 SMO 激活三聚体 G 蛋白和 CARMA1 相关信号复合物,导致 NF-κB 激活。该信号级联反应有助于 DLBCL 的存活,可能成为 DLBCL 联合治疗的潜在靶点。